Vertex Pharmaceuticals (VRTX) Cash from Financing Activities (2009 - 2026)

Vertex Pharmaceuticals' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at -$538.8 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 20.81% year-over-year to -$538.8 million in Q1 2026; TTM through Mar 2026 was -$2.1 billion, a 16.61% decrease from a year earlier, with the FY2025 full-year figure at -$2.3 billion, down 51.27% from the prior year.
• Cash from Financing Activities fell to -$538.8 million in Q1 2026 per VRTX's latest filing, from -$77.2 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $47.7 million in Q2 2022 and bottomed at -$1.2 billion in Q3 2025.
• The 5-year median for Cash from Financing Activities is -$294.7 million (2023), against an average of -$289.7 million.
• Across the five-year window, Cash from Financing Activities surged 111.96% in 2022 and sank 2172.83% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at $40.2 million in 2022, then tumbled by 398.01% to -$119.8 million in 2023, then slumped by 226.63% to -$391.3 million in 2024, then jumped by 80.27% to -$77.2 million in 2025, then sank by 597.93% to -$538.8 million in 2026.
• Per Business Quant, the three latest VRTX Cash from Financing Activities figures stand at -$538.8 million (Q1 2026), -$77.2 million (Q4 2025), and -$1.2 billion (Q3 2025).